The highest score in the Prescription Justice Congressional Report Card on Drug Prices – 100 – goes to Representative Jan Schakowsky (D-IL), with a grade of A+. The only other A+ in the House goes to Rep. Perter Welch (D-VT), who landed a score of 99.5.
Rep. Tom Malinowski (D-NJ7) is one of a very small number of members of the U.S. House of Representatives to receive an A- in our Congressional Report Card on Drug Prices. Only 16 other House members received an A-, A or A+. The congressman’s high grade is based on his voting record and because he has taken the Prescription Justice Pledge, proclaiming support for the Prescription Justice Policy Platform on lowering drug prices. We applaud Rep. Malisnowski for his actions to help end the crisis of high drug prices in America!
While the coronavirus pandemic is the most pernicious public health crisis of our time, for decades now the crisis of high drug prices is a ubiquitous feature of the American healthcare landscape. Young adults dying because they can’t afford insulin; people burdened with battling cancer facing bankruptcy due to the price of cancer drugs; patients going to the emergency rooms because they did not take heart medications due to cost; parents faced with the decision of whether or not they can afford a new Epipen, as their old one faces expiration, and the list goes on and on. We are outraged by the greed of the pharmaceutical industry, but we cannot vote in and out of office their CEOs and other executives. But we can do just that when it comes to Congress. To help, Prescription Justice has created the Drug Prices Congressional Report Card in which we have graded all members of the U.S. Congress, House and Senate, on their action or inaction on drug prices.
Gabriel Levitt, President of Prescription Justice submitted comments to the Food and Drug Administration (FDA) in response to the Notice of Proposed Rulemaking (NPRM) titled "Importation of Prescription Drugs, FDA-2019-N-5711, 84 Fed. Reg. 70796.
Prescription Justice founder Gabriel Levitt submitted the comments below in response to the FDA’s request for comments on its draft guidance related to “Importation of Certain FDA-Approved Human Prescription Drugs, Including Biological Products, under Section 801(d)(1)(B) of the Federal Food, Drug, and Cosmetic Act: Draft Guidance for Industry.”